Fulcrum Therapeutics (FULC) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Downgraded | Overweight → Underweight | — | Jun 3, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | $3.00 from $25.00 | Jun 2, 2026 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $4.00 from $24.00 | Jun 2, 2026 |
| Truist Securities | Downgraded | Buy → Hold | $4.00 from $17.00 | Jun 2, 2026 |
| Piper Sandler | Downgraded | Overweight → Underweight | $3.00 from $23.00 | Jun 2, 2026 |
| Stifel | Downgraded | Buy → Hold | $3.00 from $25.00 | Jun 2, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $20.00 | Jan 12, 2026 |
| Truist Securities | Maintained | Buy | $18.00 from $14.00 | Dec 11, 2025 |
| B of A Securities | Maintained | Underperform | $7.00 from $6.00 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $18.00 | Dec 8, 2025 |
| Piper Sandler | Maintained | Overweight | $23.00 from $16.00 | Dec 8, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $24.00 from $15.00 | Dec 8, 2025 |
| RBC Capital | Maintained | Sector Perform | $10.00 from $7.00 | Dec 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $12.00 | Nov 24, 2025 |
| Truist Securities | Initiated Coverage | Buy | $14.00 | Nov 24, 2025 |
| Piper Sandler | Maintained | Overweight | $16.00 from $12.50 | Oct 30, 2025 |
| RBC Capital | Maintained | Sector Perform | $7.00 from $5.00 | Oct 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 | Oct 20, 2025 |
| RBC Capital | Maintained | Sector Perform | $5.00 from $4.00 | Jul 30, 2025 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $12.00 from $4.00 | Jul 29, 2025 |
Frequently asked questions
What is the price target for FULC stock?
The average 12-month analyst price target for Fulcrum Therapeutics (FULC) is $3.40, with a high estimate of $4.00 and a low of $3.00, across 5 analysts.
Is FULC a buy, sell, or hold?
Analysts covering Fulcrum Therapeutics currently average a Hold rating: 1 buy, 5 hold and 1 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for FULC?
The average price target of $3.40 implies 11.69% downside from the last price of $3.85.
What is the latest analyst rating on FULC?
On Jun 3, 2026, JP Morgan downgraded Fulcrum Therapeutics to Underweight.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.